Abstract

Prostate cancer remains a leading cause of cancer morbidity and mortality among men worldwide, characterized 
by substantial genomic heterogeneity that complicates diagnosis, prognosis, and treatment selection. While short
read sequencing technologies have enabled important advances in genomic profiling, they are limited in detecting 
complex structural variations and repeat-rich regions that are critical for therapy guidance. Long-read sequencing 
has emerged as a transformative approach, offering enhanced resolution of structural rearrangements, haplotype 
phasing, and comprehensive genome characterization. This paper explores the translational pathway from 
genomic discovery to clinical care through the implementation of long-read sequencing-guided therapy selection 
in prostate cancer, with particular emphasis on diverse populations. It examines the principles and advantages of 
long-read technologies, their integration into clinical workflows, and their role in identifying actionable genomic 
alterations and resistance mechanisms. The study further highlights the importance of equitable representation in 
genomic datasets, addressing disparities in access to sequencing technologies and targeted therapies. Ethical, legal, 
and data governance considerations are also discussed, particularly in relation to population-specific genomic data. 
Despite promising advances, challenges remain in standardization, cost, bioinformatics infrastructure, and health 
system integration. The paper concludes that long-read sequencing holds significant potential to enhance 
precision oncology in prostate cancer, provided that implementation strategies prioritize inclusivity, equity, and 
robust clinical translation across global populations.